Cardiovascular effects of cholecalciferol treatment in dialysis patients - A randomized controlled trial

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Mose, Frank H ^a,b   Vase, Henrik ^c   Larsen, Thomas ^a   Kancir, Anne S P ^a   Kosierkiewic, Renata ^b   Jonczy, Bartlomiej ^b   Hansen, Annebirthe B ^b   Oczachowska Kulik, Anna E ^b   Thomsen, Ingrid M ^b   Bech, Jesper N ^a,b   Pedersen, Erling B ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Blood pressure; Brain natriuretic peptide; Cardiac function; Cholecalciferol; Chronic kidney disease

Indexed keywords

ALFACALCIDOL; BRAIN NATRIURETIC PEPTIDE; CALCIUM; COLECALCIFEROL; ERYTHROPOIETIN; PARICALCITOL; PHOSPHATE BINDING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MONITORING; CARDIOVASCULAR EFFECT; CHRONIC PATIENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VITAMIN SUPPLEMENTATION;

AGED; BLOOD PRESSURE; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PLACEBO EFFECT; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VITAMIN K DEFICIENCY; VITAMINS;

EID: 84899089999     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-50     Document Type: Article

References (45)

1. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, Nybo M, Rasmussen LM, Hansen D, Scholze A, Nephrol Dial Transplant 2012 27 3523 3531 10.1093/ndt/gfs138 22822092
2. Vitamin D deficiency and anemia in early chronic kidney disease. Patel NM, Gutierrez OM, Andress DL, Coyne DW, Levin A, Wolf M, Kidney Int 2010 77 715 720 10.1038/ki.2009.551 20130525
3. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A, Clin J Am Soc Nephrol 2010 5 905 911 10.2215/CJN.06510909 20203163
4. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Singer RF, Semin Dial 2013 26 40 46 10.1111/sdi.12010 23017052
5. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A, Nephrol Dial Transplant 2009 24 611 618 18775809
6. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, Wanner C, Boeschoten EW, Brandenburg V, Nephrol Dial Transplant 2011 26 1024 1032 10.1093/ndt/gfq606 20947538
7. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J, Am J Clin Nutr 2008 87 1631 1638 18541550
8. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S, Am J Kidney Dis 2011 58 374 382 21636193
9. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D, Kidney Int 2008 74 170 179 10.1038/ki.2008.101 18385669
10. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Adams JS, Hewison M, Arch Biochem Biophys 2012 523 95 102 10.1016/j.abb.2012.02.016 22446158
11. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N, Circulation 2005 111 1666 1671 10.1161/01.CIR.0000160353. 27927.70 15795327
12. Extrarenal vitamin d activation and interactions between vitamin d2, vitamin d3, and vitamin d analogs. Jones G, Annu Rev Nutr 2013 33 23 44 10.1146/annurev-nutr-071812-161203 23642201
13. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL, Science 2006 311 1770 1773 10.1126/science.1123933 16497887
14. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y, Nephrol Dial Transplant 2004 19 179 184 10.1093/ndt/gfg513 14671054
15. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ, Li X, Bhan I, Zhao Q, Thadhani R, Li YC, Am J Pathol 2010 177 622 631 10.2353/ajpath.2010.091292 20616348
16. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE, Clin Chim Acta 2010 411 936 939 10.1016/j.cca.2010.03.004 20298685
17. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC, Custodio MR, Pecoits-Filho R, J Ren Nutr 2012 22 284 291 10.1053/j.jrn.2011.07. 001 21908203
18. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N, Am J Cardiol 1986 57 450 458 10.1016/0002-9149(86)90771-X 2936235
19. Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans. Matthesen SK, Larsen T, Vase H, Lauridsen TG, Pedersen EB, Scand J Clin Lab Invest 2012 72 78 86 10.3109/00365513.2011.635216 22149452
20. Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension. Pedersen EB, Danielsen H, Spencer ES, Eur J Clin Pharmacol 1984 26 543 547 10.1007/BF00543482 6468469
21. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Pedersen EB, Eiskjaer H, Madsen B, Danielsen H, Egeblad M, Nielsen CB, Nephrol Dial Transplant 1993 8 1064 1070 8272217
22. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK, Nephron Clin Pract 2006 102 21 c29 10.1159/000088295 16166802
23. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK, Am J Kidney Dis 1999 33 73 81 10.1016/S0272-6386(99)70260-X 9915270
24. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Dusso AS, Tokumoto M, Kidney Int 2011 79 715 729 10.1038/ki.2010.543 21270766
25. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C, Nephron Clin Pract 2008 110 58 c65 10.1159/000151534 18724068
26. Extra-renal production of calcitriol in chronic renal failure. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E, Kidney Int 1988 34 368 375 10.1038/ki.1988.190 3172645
27. Vitamin D receptor activation and cardiovascular disease. Gonzalez-Parra E, Rojas-Rivera J, Tunon J, Praga M, Ortiz A, Egido J, Nephrol Dial Transplant 2012 27 4 v17 iv21 23258805
28. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Margolis KL, Ray RM, Van HL, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm RH Jr, Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC, Hypertension 2008 52 847 855 10.1161/HYPERTENSIONAHA.108.114991 18824662
29. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD, Diabet Med 2008 25 320 325 10.1111/j.1464-5491.2007.02360.x 18279409
30. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Scragg R, Khaw KT, Murphy S, Eur J Clin Nutr 1995 49 640 646 7498100
31. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB, Am J Hypertens 2012 25 1215 1222 10.1038/ajh.2012.111 22854639
32. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME, JAMA Intern Med 2013
33. Is 44-hour better than 24-hour ambulatory blood pressure monitoring in hemodialysis? Martin LC, Franco RJ, Gavras I, Matsubara BB, Okoshi K, Zanati SG, Caramori JT, Barretti P, Balbi AL, Gavras H, Kidney Blood Press Res 2006 29 273 279 10.1159/000096176 17035712
34. Impact of aortic stiffness on survival in end-stage renal disease. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM, Circulation 1999 99 2434 2439 10.1161/01.CIR.99.18.2434 10318666
35. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ, Clin J Am Soc Nephrol 2013 8 1143 1149 10.2215/CJN.02840312 23493381
36. Influence of haemodialysis on variability of pulse wave velocity in chronic haemodialysis patients. Di IB, Nazzaro P, Cucciniello E, Bellizzi V, Nephrol Dial Transplant 2010 25 1579 1583 10.1093/ndt/gfp662 20031931
37. Vitamin D and human health: lessons from vitamin D receptor null mice. Bouillon R, Carmeliet G, van EE Verlinden L, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M, Endocr Rev 2008 29 726 776 10.1210/er.2008-0004 18694980
38. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC, Kidney Int 2008 74 1577 1581 10.1038/ki.2008.452 19034301
39. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. Larsen T, Mose FH, Bech JN, Pedersen EB, BMC Nephrol 2013 14 163 10.1186/1471-2369-14-163 23889806
40. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. de ZD Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D, Lancet 2010 376 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
41. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C, Nephrol Dial Transplant 2008 23 3670 3676 10.1093/ndt/gfn339 18579534
42. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Jean G, Souberbielle JC, Chazot C, Nephrol Dial Transplant 2009 24 3799 3805 10.1093/ndt/gfp370 19622574
43. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC, Nephrol Dial Transplant 2008 23 4016 4020 10.1093/ndt/gfn367 18593741
44. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD, J Am Soc Nephrol 2010 21 353 361 10.1681/ASN.2009040451 20007751
45. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Shah N, Bernardini J, Piraino B, Perit Dial Int 2005 25 362 366 16022093